FibroBiologics, Inc. (FBLG) insider buys 140,000 shares at $0.34 on 12/11/2025

Rhea-AI Filing Summary

FibroBiologics, Inc. insider activity shows that general counsel Ruben A. Garcia purchased 140,000 shares of common stock on December 11, 2025. The Form 4 reports this as a purchase coded “P” at a weighted average price of $0.34 per share, with individual trade prices ranging from $0.3333 to $0.3504. After these transactions, Garcia beneficially owns 140,000 shares of FibroBiologics common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GARCIA RUBEN A

(Last) (First) (Middle)

C/O FIBROBIOLOGICS, INC.

455 E. MEDICAL CENTER BLVD., SUITE 300

(Street)

HOUSTON, TX 77598

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		P		140,000	A	$0.34(1)	140,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3333 to $0.3504 on December 11, 2025. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Ruben A. Garcia	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did FibroBiologics (FBLG) report in this Form 4?

The filing reports that general counsel Ruben A. Garcia purchased 140,000 shares of FibroBiologics common stock on December 11, 2025, coded as a purchase (“P”).

Who is Ruben A. Garcia in relation to FibroBiologics (FBLG)?

Ruben A. Garcia is identified as an officer of FibroBiologics, Inc., serving as General Counsel, and he is the sole reporting person on this Form 4.

How many FibroBiologics (FBLG) shares did the insider buy and at what price?

Ruben A. Garcia bought 140,000 shares of FibroBiologics common stock at a weighted average price of $0.34 per share, with trade prices between $0.3333 and $0.3504 on December 11, 2025.

How many FibroBiologics (FBLG) shares does Ruben A. Garcia own after the transaction?

Following the reported purchase, Ruben A. Garcia beneficially owns 140,000 shares of FibroBiologics common stock, shown in the filing as held directly.

Is this FibroBiologics (FBLG) Form 4 filed by one or multiple reporting persons?

The Form 4 indicates that it is filed by one reporting person, with the box checked for “Form filed by One Reporting Person.”

Were multiple trades involved in the FibroBiologics (FBLG) insider purchase?

Yes. The explanation states the $0.34 price is a weighted average and that the shares were purchased in multiple transactions at prices ranging from $0.3333 to $0.3504 on December 11, 2025.